EQS-News

M1 Kliniken AG: Strong profit growth in 2023 underlines ambitious plans for global market leadership in medical aesthetics

EQS-News: M1 Kliniken AG / Key word(s): Annual Report/Forecast M1 Kliniken AG: Strong profit growth in 2023 underlines ambitious plans for global market leadership in medical aesthetics 23.05.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG: Strong profit growth in 2023 underlines ambitious plans for global market leadership in medical aesthetics 

 

• Group sales increase by 10.9% to € 316.3 million in 2023
• Highly profitable beauty segment drives growth with an increase of 17.6% to EUR 70.8 million
• Consolidated net profit (after minority interests) improved from EUR 4.3 million to EUR 10.3 million
• Dividend proposal of EUR 0.50 per share
• Medium-term forecast for the Beauty segment: target sales of EUR 200 to 300 million by 2029 with an EBIT margin of at least 20%

 

Berlin, 23 May 2024 - M1 Kliniken AG (ISIN: DE000A0STSQ8) today published its annual report for the year 2023. The M1 Group continued its steady growth course in the reporting period, with the highly profitable Beauty segment making a significant contribution to its success. Consolidated net profit (after minority interests) doubled in 2023, and the M1 Group also sees considerable growth potential for the coming years.

The medium-term outlook for the Beauty segment anticipates sales growth reaching between EUR 200 and 300 million.  The goal is for the "M1 Med Beauty" brand to become the world's leading private provider of beauty treatments within the Group by this time at the latest. M1 Med Beauty is already the market leader in Europe, offering outstanding service at the best price.

 

Consolidated net profit (after minority interests) more than doubled
 

In the 2023 financial year, the M1 Group recorded an impressive 10.9% increase in sales to EUR 316.3 million compared to EUR 285.3 million in the previous year. The Beauty segment once again proved to be a strong growth driver with a 17.6% increase in sales to EUR 70.8 million. Consolidated earnings before interest and taxes (EBIT) grew faster than sales by 68.5% to 15.7 million euros compared to 9.3 million euros in the previous year. Consolidated net profit (after minority interests) rose from EUR 4.3 million to EUR 10.3 million in 2023, which corresponds to a significant doubling. Accordingly, consolidated net profit (after minority interests) per share increased from EUR 0.24 to EUR 0.54. The Group's equity ratio was a solid 67.3% as at the balance sheet date of 31 December 2023. In view of the profitable growth and high equity ratio, the Executive Board and Supervisory Board recommend a dividend distribution of EUR 0.50 per share.